Sutro Biopharma Inc（STRO）财务数据STROSutro Biopharma Inc

Evaluating the bottom line, Sutro Biopharma Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -301.73%, while the net margin is -391.64%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively STRO converts its operational activities into shareholder value.

In the context of the broader market, STRO competes directly with industry leaders such as ABEO and IKT. With a market capitalization of $353.34M, it holds a leading position in the sector. When comparing efficiency, STRO's gross margin of 100.00% stands against ABEO's 63.30% and IKT's N/A. Such benchmarking helps identify whether Sutro Biopharma Inc is trading at a premium or discount relative to its financial performance.

In Q2 2026, Sutro reported revenues of $9.8 million, down from $63.7 million in Q2 2025, highlighting a significant decline in collaboration revenue. The company has maintained a gross margin of 100% across its reporting periods, indicating effective cost management in production despite the revenue drop.